Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation

被引:8
|
作者
Vrachimis, A. [1 ]
Schober, O. [1 ]
Riemann, B. [1 ]
机构
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2012年 / 51卷 / 03期
关键词
Radioiodine; remnant ablation; thyroid hormone withdrawal; rhTSH; RECOMBINANT HUMAN THYROTROPIN; HORMONE WITHDRAWAL; FOLLOW-UP; CARCINOMA; THERAPY; HYPOTHYROIDISM; RISK; MANAGEMENT; RHTSH; COST;
D O I
10.3413/Nukmed-0432-11-10
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: Radioiodine remnant ablation (RRA) after (near-)total thyroidectomy (TE) is a key element in patients with differentiated thyroid cancer (DTC). The use of exogenous TSH stimulation (rhTSH) prior to RRA has shown promising results as compared to conventional thyroid hormone withdrawal (THW). As yet, the efficacy of RRA after brief THW and single rhTSH administration has not been assessed. Patients, methods: The study sample comprised 147 patients with DTC referred to our center between May 2008 and September 2010. All patients received TE with subsequent RRA. None of these 147 patients had evidence of distant metastasis. 93 patients had endogenous TSH stimulation 4-5 weeks after surgery (group I) and twenty-six received two rhTSH injections (group II). 28 patients were treated with a single rhTSH injection after a brief THW (group III). RRA-Efficacy was assessed three months after therapy by diagnostic whole-body scan and measurement of the tumour marker thyroglobulin (Tg) under TSH stimulation. Results: Three categories of success were defined for remnant ablation. Based on the definition of successful remnant ablation no visible uptake and a Tg <= 2.0 ng/ml (category 1) was seen in 62/93 patients in group I, in 17/26 patients in group II (p = n.s.) and in 12/28 patients in group III (p < 0.05). Visible radioiodine uptake and a Tg <= 2.0 ng/ml (category 2) was seen in 16/28 patients of group III and thus significantly more frequent than in group I (28/93 patients) (p < 0.01). However, patients in group III (16/28 patients) and group II (8/26 patients) showed no significant difference in this category (p = n.s.). Visible radioiodine uptake and a Tg > 2.0 ng/ml (category 3) was found in 3/93 patients in group I and 1/26 patients in group II but in no patient in group III. Conclusion:The third strategy of remnant ablation using a single injection of rhTSH after a brief THW period resulted in a significant higher rate of patients with residual uptake in the thyroid bed and a Tg level below 2 ng/ml three months after remnant ablation in comparison to THW. However, the overall efficacy of the third protocol was not significantly different as compared to two rhTSH injections. Under the aspect of the supply shortage of rhTSH the combined endogenous and exogenous TSH stimulation may be an attractive alternative for remnant ablation in differentiated thyroid cancer.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [31] Hospitalization costs for two methods of TSH stimulation during the radioiodine ablation in thyroid cancer patients
    Borger, I
    Schlumberger, M.
    Ricard, M.
    Remy, H.
    Allyn, M.
    De Pouvourville, G.
    VALUE IN HEALTH, 2007, 10 (06) : A323 - A323
  • [32] Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
    Lv, Rong-Bin
    Wang, Qing-Gang
    Liu, Chao
    Liu, Fang
    Zhao, Qing
    Han, Jian-Guo
    Ren, Dao-Ling
    Liu, Bin
    Li, Cheng-Li
    ONCOTARGETS AND THERAPY, 2017, 10 : 4051 - 4057
  • [33] Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods
    Casas, Juan Antonio Vallejo
    Mena Bares, Luisa M.
    Galvez, Maria Angeles
    Marlowe, Robert J.
    Romero, Jose M. Latre
    Martinez-Paredes, Maria
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (09) : 840 - 846
  • [34] Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients
    Castagna, M. G.
    Cantara, S.
    Pacini, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (10) : 1087 - 1094
  • [35] Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients
    M. G. Castagna
    S. Cantara
    F. Pacini
    Journal of Endocrinological Investigation, 2016, 39 : 1087 - 1094
  • [36] Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
    Forleo, R.
    Fralassi, N.
    Maino, F.
    Capezzone, M.
    Brilli, L.
    Pilli, T.
    Cantara, S.
    Castagna, M. G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (01) : 139 - 144
  • [37] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    Berg, G
    Lindstedt, G
    Suurküla, M
    Jansson, S
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) : 44 - 52
  • [38] Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis
    Fu, H.
    Ma, C.
    Tang, L.
    Wu, F.
    Liu, B.
    Wang, H.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (01): : 121 - 128
  • [39] Thyroglobulin Flare Response After Radioiodine Ablation in 2 Patients With Differentiated Thyroid Cancer
    Tsang, James F.
    Levin, Daniel P.
    Leslie, William D.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (05) : 421 - 422
  • [40] Thyroxine Dosing after I131Radioiodine Ablation for Differentiated Thyroid Cancer
    Clarke, K.
    Gill, V.
    Gerrard, G.
    CLINICAL ONCOLOGY, 2011, 23 (08) : 559 - 560